Clinical Trials - Physician

Clinical Trials - Physician

Use the search below to find a complete list of what is available in our state and who you can contact for more information.

Title Phase Contact(s)
Pilot Study Evaluating Activity of the Combination of Anti-PD-1 Antibody with High Dose IL-2 in Metastatic Melanoma (MMP-MEL16-261) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields) in Combination with PD-1 Inhibitors or Docetaxel, for Second Line Treatment of Non-Small Cell Lung Cancer (EF-24) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields Concomitant with Gemcitabine and nab-Paclitaxel for Front-Line Treatment of Locally-Advanced Pancreatic Adenocarcinoma (Panova-3) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Prospective Research Assessment in Multiple Myeloma: An observational Evaluation III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients with Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy (INCB-MA-MF-401) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Protocol for a Research Database for Hematopoietic Cell Transplantation and Cellular Therapies (CIBMTR Research Database) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Qualitative Interviews in Patients with Smoldering Multiple Myeloma and Patients with Multiple Myeloma (EVA-21335) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer (HCRN BRE12-158) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive, HER2 Neg, Breast Cancer (A011502) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Placebo-Controlled Study of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk, HR+, HER2 Neg, Breast Cancer (S1207) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Abemaciclib Combined with Standard Adj Endocrine Therapy vs Standard Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, HR+, HER2 Neg, Breast Cancer (B58) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in NonSmall Cell Lung Cancer (EA5142) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Olaparib vs Placebo as Adjuvant Treatment in Patients with BRCA 1, 2 Mutations and High Risk HER2 Neg Primary Breast Cancer Who Have Completed Definitive Local Treatment and Adj or NeoAdj Chemotherapy (B55) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study of Tesetaxel Plus Capecitabine vs Capecitabine Alone in Patients with HER2 Neg, HR+, Locally Advanced or Metastatic Brast Cancer Previously Treated with a Taxane (ODO-TE-B301) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma (16065) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (A011401) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High Risk Node Negative Triple Negative Invasive Breast Cancer (BR003) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Adjuvant Radiotherapy with or without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (EA3132) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Bortezomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone Followed by Limited or Indefinite Lenalidomide Maintenance Therapy in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (E1A11) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Erlotinib vs Placebo in Patients with Completely Resected EGFR Mutant NonSmall Cell Lung Cancer (A081105) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer (S1706) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair (A021502) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized, Controlled, Open-Label, Clinical Study of Pevonedistat Plus Azacitidine versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low(Pevonedistat-3001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Randomized, Double-Blinded, Controlled Study of ONT- 380 vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (ONT-380-206) II
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Single Arm, Open-Label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic GU Cancers (SGN22E-001) III
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850

Pages

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members